ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
Published: The authors examined risk association between Parkinson’s disease and cancer using data from 63 publications, totaling in 17 million individuals. With the exception of melanoma, the authors found that the risk association of Parkinson’s disease and cancer was inversely related.
This protocol details methods for the unilateral intranigral AAV alpha-synuclein injection.
DOPA pheomelanin is increased in neuromelanin of Parkinson’s disease substantia nigra and it exacerbates alpha-synuclein neurotoxicity
Preprint: Neuromelanin in the substantia nigra may be a key factor contributing to dopaminergic neuron vulnerability in Parkinson’s disease. Neuromelanin consists of pheomelanin and eumelanin moieties. Here, the authors investigated the relative composition and specific roles of pheomelanin and eumelanin moieties of NM in PD.